On the evening of December 17, Enhua Pharmaceutical issued an announcement that it recently received the "Notice of Approval of Drug Supplement application" on "Sulpiride Tablets" approved by the State Food and Drug Administration, approving the drug to pass the consistency evaluation of generic drug quality and efficacy.
The announcement shows that supilide tablets are used to treat schizophrenia, which has a certain effect on depressive symptoms, and other uses have anti-nausea. Up to now, the company has invested about 7.03 million yuan in research and development costs in the consistency evaluation project of shupilil tablets. (Wu Wenfeng)
![Announcement #Enhua Pharmaceutical a new drug of anesthesia class 1 was approved for clinical trials[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)